The present invention provides a pharmaceutical composition that can improve the survival time and the survival rate of a patient after onset of hemorrhagic shock. The present invention provides a gaseous pharmaceutical composition comprising hydrogen gas for improving and/or stabilizing circulatory dynamics after onset of hemorrhagic shock. The pharmaceutical composition of the present invention can be administered when blood transfusion therapy cannot be given, and can increase the survival rate after onset of hemorrhagic shock or extend the survival time compared to when the pharmaceutical composition of the present invention is not administered.